DeFlame Enterprises » Products » Nutritional Supplements » Osatate - Calcium Complex

$26.00

Loading Updating cart...

Nutritional Supplements

Osatate – Calcium Complex

Osatate is a microcrystaline hydroxyapatite calcium (MCH-Cal) supplement. Two to three tablets are typically taken per day. One tablet contains 225 mg of calcium. There are 100 tablets per bottle, which allows for a 1-2 month supply.

Click here to see the full Osatate label

 

Microcrystaline hydroxyapatite-calcium (MCH-Cal) research

Calcium is perhaps the most well known and most commonly taken supplements. MCH-Cal is a unique calcium supplement in that it is derived from whole bone and contains an organic and inorganic component. The organic component consists of collagen, glycosaminoglycans, peptides, and growth factors for bone. The inorganic component contains predominately calcium and phosphorus. Research suggests that MCHC is the best source for calcium to help maintain normal bone density (1-4).

Bone health requires the anti-inflammatory diet and additional supplements, such as vitamin D, vitamin K, magnesium, and omega-3 fatty acids. Thus, it is best to take Osatate-Calcium Complex with either the Basic or Advanced Health Promotion supplement program. 

The osteoporosis section of Deflame.com discusses bone health nutrients in more detail.

 

References

1. Pines A, Raafat H, Lynn AH, Whittington J. Clinical trial of microcrystalline hydroxyapatite compound (dOssopanT) in the prevention of osteoporosis due to corticosteroid therapy. Curr Med Res Opin. 1984;8:734-42. 
2. Stellon A, Davies A, Webb A, Williams R. Microcrystalline hydroxyapatite compound in prevention of bone loss in corticosteroid-treated patients with chronic active hepatitis. Postgrad Med J. 1985;61:791-6. 
3. Ruegsegger P, Keller A, Dambacher MA. Comparison of the treatment effects of ossein-hydroxyapatite compound and calcium carbonate in osteoporotic females. Osteoporosis Int. 1995;5:30-4.
4. Castelo-Branco C, Pons F, Vicente JJ, Sanjuan A, Vanrell JA. Preventing postmenopausal bone loss with ossein-hydroxyapatite compounds. Results of a two-year prospective trial. J Reprod Med. 1999; 44(7):601-5.

LoadingUpdating...